Metabolic Syndrome Negatively Impacts Stone-Specific Quality of Life

Jonathan R.Z. Lim, Kymora B. Scotland, Seth K. Bechis, Roger L. Sur, Stephen Y. Nakada, Jodi A. Antonelli, Necole M. Streeper, Sri Sivalingam, Davis P. Viprakasit, Timothy D. Averch, Jaime Landman, Thomas Chi, Vernon M. Pais, Vincent G. Bird, Sero Andonian, Naeem Bhojani, Noah E. Canvasser, Jonathan D. Harper, Kristina L. Penniston, Ben H. Chew

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Purpose: Metabolic syndrome (MetS) is a cluster of metabolic diseases that is linked to atherosclerotic cardiovascular disease. MetS has also been linked to increased nephrolithiasis. However, limited research has been conducted on MetS and its impact on stone-specific health-related quality of life (HRQOL). This study aims to examine the hypothesis that the presence of MetS is associated with decreased HRQOL. Materials and Methods: The Wisconsin Stone Quality of Life Questionnaire, a stone-specific HRQOL questionnaire, was used to survey 3051 patients with kidney stones. Medical history was collected from patients. These data were used to distinguish MetS patients from non-MetS patients. Among patients with current stones, a Wilcoxon rank sum test was used to compare HRQOL scores from MetS patients and non-MetS patients. HRQOL from patients with and without individual MetS components were also compared, and a multivariate analysis was conducted. Results: Statistical comparison between MetS patients (median score 102/140) and non-MetS patients (median score 106/140) demonstrated a lower stone-specific HRQOL in patients with MetS (p = 0.049). Among individual MetS components, patients with diabetes mellitus (DM) or body mass index (BMI) >30 had significantly lower HRQOL than patients without DM or BMI <30 (p = 0.028 and p < 0.001, respectively). The multivariate analysis supported this trend as MetS remained a significant predictor of decreased HRQOL (p = 0.002) after controlling for other variables assessed. Conclusions: This study indicates an association between MetS and a lower stone-specific QOL. This has important implications for stone prevention strategies in patients with MetS. Clinical Trial Registration number: H14-01143

Original languageEnglish (US)
Pages (from-to)1203-1210
Number of pages8
JournalJournal of Endourology
Issue number11
StatePublished - Nov 1 2020

All Science Journal Classification (ASJC) codes

  • Urology


Dive into the research topics of 'Metabolic Syndrome Negatively Impacts Stone-Specific Quality of Life'. Together they form a unique fingerprint.

Cite this